Nivolumab for the treatment of renal-cell carcinoma
Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L
Record ID 32016001111
Spanish
Authors' recommendations:
No evidence has been identified on the use of nivolumab as first-line treatment or in localized renal-cell carcinoma stage.
High-quality evidence, coming from a single study in patients with clear cell histology, indicates that nivolumab would result in an additional benefit on overall survival of approximately six months, with better tolerance than the available comparators in patients with advanced renal-cell carcinoma who have progressed despite antiangiogenic therapy.
The coverage policies found all come from the United States private sponsors, providing coverage in patients with advanced renal-cell carcinoma which has progressed despite antiangiogenic therapy. In Canada, coverage is recommended only under and price-reduction agreement as it is not cost-effective at its current price.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Nivolumab
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.